This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Norbert Lamping: Innovator in Biotechnology
Introduction
Norbert Lamping is a notable inventor based in Holzkirchen, Germany. He has made significant contributions to the field of biotechnology, particularly in the area of recombinant protein expression. His innovative work addresses critical challenges faced in this domain.
Latest Patents
Norbert Lamping holds a patent for a Multi-copy gene protein expression system. This invention focuses on two prevalent issues in recombinant protein expression: the low quantity of protein produced and the genetic instability of cell lines used for this purpose. The core principle of his invention involves introducing multiple expression cassettes into a cell. Each of these cassettes codes for the same mature recombinant protein of interest but features different nucleotide sequences. An expression cassette is defined as a polynucleotide sequence that includes at least a promoter sequence, a start codon, a coding sequence for the protein intended for recombinant expression, a stop codon, and a terminator.
Career Highlights
Norbert Lamping is associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to further his research and development in biotechnology, contributing to advancements in the field.
Collaborations
Some of his notable coworkers include Clemens Achmüller and Matjaz Vogelsang. Their collaboration has likely fostered an environment of innovation and shared expertise in their projects.
Conclusion
Norbert Lamping's contributions to biotechnology, particularly through his patented Multi-copy gene protein expression system, highlight his role as an innovator in the field. His work continues to influence advancements in recombinant protein expression.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
